As Inflammatory Bowel Disease (IBD) severity increases in patients entering studies, trial design is becoming more complex – and finding the right patients is a continuing challenge. Higher risk profiles of new biologics are forcing a tighter focus on safety issues, and market attractiveness is driving strong competition. So how can drug developers successfully overcome the myriad challenges you face? As a market leader in conducting IBD studies across the lifecycle and around the globe, Quintiles has the experience and therapeutic and operational expertise to help you take your IBD therapy from lab to market.
Fact Sheet May 12, 2014